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Summary
Neuropathic pain refers to pain that orginates from pathology of the nervous system. 
Common causes of neuropathic pain are diabetes mellitus, reactivation of herpes zoster, 
nerve compression or radiculopathy, alcohol, chemotherapy or abuse of some drugs 
and trigeminal neuralgia. 
Specific symptoms of neuropathic pain are mechanical allodynia and cold hyperlgesia. 
Drugs to treat neuropathic pain can be divided into adjuvent analgesics (antidepres-
sants and anticonvulsants), opioids and topical agents. The use of multiple drug thera-
pies is common in practice. 
Despite considerable increase in the number of randomized placebo-controlled 
trials in neuropathic pain over the last few years, the medical treatment of neuropathic 
pain is still far from being satisfactory, with kless than half of patients achieving signifi-
cant benefit with any pharmacological drug. 
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IntroductIon
Neuropathic pain is defined as ‘pain initiated or caused by a primary lesion 
or dysfunction of the nervous system’ [1]. It can be a debilitating and difficult 
condition to treat and is often resistant to simple analgesics, requiring additional 
analgesic approaches [2]. It is not only devastating for patients but also places 
considerable demands on society, including financial burdens relating to health-
care costs, workplace disruption, disability and benefits [3].
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neuropathic pain mechanisms
Neuropathic pain is generated by electrical hyperactivity of neurons along 
the pain pathways. The sensory pathway consists of at least three neurons, and 
lesions anywhere along the pathway can lead to neuropathic pain. Changes in 
expression of neuronal ion channels and receptors, synaptic connectivity, and 
anatomy all contribute to neuropathic pain (neural plasticity) [4,5].
Clinical investigations of pain mechanisms are labor intensive and require 
specialized equipment; thus, they are not yet practical for routine clinical use. 
Even in specialized pain research settings, it is difficult to identify specific neu-
ropathic pain mechanisms. A simple focal peripheral nerve injury unleashes a 
range of peripheral and central nervous system processes that can all contribute 
to persistent pain and abnormal sensation [6].
Inflammation, reparatory mechanisms of neural tissues in response to injury, 
and the reaction of adjacent tissues to injury lead to a state of hyperexcitability 
in primary afferent nociceptors, a phenomenon termed peripheral sensitization. 
In turn, central neurons innervated by such nociceptors undergo dramatic func-
tional changes including a state of hyperexcitability termed central sensitiza-
tion. Normally these sensitization phenomena extinguish themselves as the tis-
sue heals and inflammation subsides. However, when primary afferent function 
is altered in an enduring way by injury or disease of the nervous system, these 
processes persist and may be highly resistant to treatment [7,8]. 
Injury or permanent loss of primary afferent fibers (deafferentation) differ-
entiates peripheral neuropathic pain from other types of pain. Positive sensory 
phenomena (spontaneous pain, allodynia, and hyperalgesia) that are charac-
teristic of patients with neuropathic pain are likely to have many underlying 
mechanisms, including ectopic generation of impulses as well as the de novo 
expression of neurotransmitters and their receptors and ion channels. Direct 
injury to central structures may permanently alter sensory processing, and in 
some patients it causes central neuropathic pain and dysesthesias. The mecha-
nisms underlying central neuropathic pain, however, are still unclear [9-11].
Increased understanding of the underlying mechanisms has allowed the 
identification of new pharmacological targets and the development of new neu-
ropathic medications but, at present, this has not helped to work out which pa-
tients are likely to respond to individual treatments. 
diagnosis of neurpathic pain
Neuropathic pain syndromes typically have both negative and positive sen-
sory symptoms and signs [12]. Nonsensory neurological symptoms and signs 
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depend on the underlying cause and may independently contribute to pain and 
disability. Although neuropathic pain has been defined by the International As-
sociation for the Study of Pain as pain “initiated or caused by a primary lesion or 
dysfunction in the nervous system,” several investigators have recently argued 
that the inclusion of the term dysfunction makes this definition vague and un-
acceptably broad [5]. A proposed solution is to define neuropathic pain as pain 
caused by a lesion of the peripheral or central nervous system (or both) manifest-
ing with sensory symptoms and signs. Demonstrating a lesion of the nervous 
system compatible with particular symptoms and signs provides strong support 
for considering the pain to be neuropathic. However, when no lesion can be 
demonstrated, the limits of current diagnostic technology do not always allow 
the possibility of neuropathic pain to be excluded. The diagnosis of neuropathic 
pain is based on a medical history, review of systems, physical and neurological 
examination, and appropriate laboratory studies including blood and serologic 
tests, magnetic resonance imaging, and electrophysiologic studies [13]. In some 
instances, nerve or skin biopsy is necessary to directly visualize nerve fibers. 
Our ability to translate pain complaints and sensory findings into specific 
pathophysiologic mechanisms that have treatment implications is in its infancy 
[14,15]. 
treatment
Regardless of the couse, neuropathic pain affects multiple aspects of a pa-
tient’s life. The managment of neuropathic pain involves a multidisciplinary ap-
proch. The therapy of neuropathi pain include use of both non-interventional 
(pharmacological, psychological, and physical therapy) as well as interventiona 
therapies. 
Without concern for diagnosis, rehabilitation, and psychosocial issues, treat-
ment has a limited chance of success. For peripheral nerve lesions, mobiliza-
tion is needed to prevent trophic changes, disuse atrophy, and joint ankylosis. 
Surgery may be needed to alleviate compression. Psychologic factors must be 
constantly considered from the start of treatment. Anxiety and depression must 
be treated appropriately. When dysfunction is entrenched, patients may benefit 
from the comprehensive approach provided by a pain clinic.
Pharmacotherapy
The best clinical approach to applied pharmacology currently incorporates 
empiric observation and identification of possible mechanisms of the neuro-
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pathic lesion and then uses the best available pharmacologic informtionto match 
these potential disease mechanisms with putative drug mechanisms. Although 
monotherapy is the ideal approach, rational polypharmacy is often pragmati-
cally used.
Several classes of drugs are moderately effective, but complete or near-com-
plete relief is unlikely. Antidepressants and anticonvulsants are most commonly 
used. Evidence of efficacy is strong for several antidepressants and anticonvul-
sants. 
Opioid analgesics can provide some relief but are less effective than for noci-
ceptive pain; adverse effects may prevent adequate analgesia. Topical drugs and 
a lidocaine – containing patch may be effective for peripheral syndromes. Sym-
pathetic blockade is usually ineffective except for some patients with complex 
regional pain syndrome [16,17].
antIdePressants 
The tricyclic antidepressants (TCAs) are often regarded as first-line drugs for 
neuropathic pain. A recent systematic review of the literature, in which num-
bers needed to treat (NNTs) of treatments for different neuropathic pain syn-
dromes were calculated, has found TCAs the most efficacious drugs for neuro-
pathic pain (NNT 3.1; 95% confidence interval (CI) 2.7-3.7) [19,20]. This is based 
on results from no less than 15 placebo-controlled designed trials, which have 
uniformly demonstrated efficacy of amitriptyline, nortriptyline, desipramine, 
chlomipramine, imipramine and maprotiline, at a daily dose range of 30-200mg, 
for PHN and DPN [21]. The main drawback of these trials is the small number 
of recruited patients in each of them. Yet, taken together, they provide strong 
level of evidence for efficacy. Notably, two small trials have found TCAs superior 
to placebo for central post-stroke pain and post-mastectomy neuropathic pain, 
whereas several others failed to demonstrate efficacy for spinal-cord injury pain, 
Human Immunodeficiency Virus (HIV) neuropathy and phantom limb pain. 
Unfortunately, TCAs are associated with numerous adverse events and are not 
tolerated by many patients. When used, slow titration is required, especially in 
the elderly [22].
Two trials have demonstrated efficacy of the selective serotonin reuptake 
inhibitors (SSRIs) citalopram and paroxetine (both at 40mg/day) in DPN [23]. In 
another trial, fluoxetine was equal to placebo [24]. 
The selective serotonin and norepinephrine reuptake inhibitors (SNRIs) ven-
lafaxine and duloxetine are newer antidepressants that have shown effectiveness 
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for DPN at daily doses of 150- 225mg and 60-120mg, respectively. The NNTs of 
4.6 (CI 2.9-10.6) for venlafaxine and 5.2 (CI 3.7-8.5) for duloxetine are superior to 
that of the SSRIs but inferior compared to the TCAs [6]. In two large randomized 
controlled trials (RCTs) duloxetine also significantly improved sleep and quality 
of life. Its most common adverse events are nausea, somnolence, dizziness and 
constipation, which all tend to decrease over time. The drug should not be used 
concomitantly with monoamine oxidase (MAO) inhibitors or in patients with 
impaired liver function. One notable advantage of the antidepressants (with the 
exception of venlafaxine) is that they can be administered once daily [25,26].
Side effects of TCAs
The most common side-effects of tricyclic antidepressants (TCA) are dry 
mouth, constipation, sweating, dizziness, disturbed vision, drowsiness, palpita-
tion, orthostatic hypotension, sedation and urinary hesitation. More selective 
TCA such as nortriptyline are better tolerated than the non-selective ones, with 
less anticholinergic effects and sedation. A suspected association between TCA 
treatment and sudden cardiac death has raised concern; a recent epidemiological 
study found a slight increase in sudden cardiac death with TCA doses superior 
to 100 mg/day. Therefore caution is recommended for older patients, particularly 
those with cardiovascular risk factors. 
Serotonin-noradrenaline reuptake inhibitors (duloxetine, venlafaxine) are 
safer to use than TCAs and are a better option in patients with cardiac disease. 
The relative risk for withdrawal due to side-effects is weak and there is no need 
for drug level monitoring. The most frequently observed adverse events with 
duloxetine are nausea, vomiting, constipation, somnolence, dry mouth, in-
creased sweating, loss of appetite and weakness. Although immediate release 
venlafaxine is associated with adverse central nervous system (CNS) and so-
matic symptoms such as agitation, diarrhea, increased liver enzymes, hyperten-
sion and hyponatremia the extended release formulation seems to be far more 
tolerable, the main side-effects being gastrointestinal disturbances 
antIconvulsants 
In addition to the antidepressants, selected anticonvulsants are often regard-
ed as first line drugs for neuropathic pain. RCTs have shown efficacy of gabapen-
tin, pregabalin, lamotrigine, carbamazepine and, to a lesser extent, a few other 
anticonvulsants. Yet, with the exception of trigeminal neuralgia, the challenge 
of 50% pain relief in more than half of these patients is rarely met [26,27].
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The most extensively studied drug in this class is pregabalin, which has 
shown efficacy for PHN and DPN in a large number of multicentre RCTs. The ef-
fective daily dose of 300-600mg can reduce pain and improve sleep, functioning 
and quality of life. Pregabalin can be rapidly titrated. Unfortunately, the drug 
has not been studied in other types of neuropathic pain. The most commonly 
reported adverse events occurring during all controlled clinical trials were diz-
ziness, somnolence, dry mouth and edema. Weight gain can also be a problem 
in some patients [28]. 
There is also strong evidence for efficacy of gabapentin (900-3600mg/day) for 
PHN and DPN. Although less broadly studied in other syndromes, gabapentin 
has shown efficacy in HIV-associated painful neuropathy, pain in Guillain-Bar-
ré’s syndrome, phantom limb pain, cancer related neuropathic pain and com-
plex regional pain syndrome type I [27].
RCTs have shown efficacy of lamotrigine for PDN, central post stroke pain, 
trigeminal neuralgia (TN) and mixed neuropathies, and of carbamazepine and 
oxcarbazepine for TN, PDN and mixed neuropathies The need for a relatively 
slow titration and the adverse effect profile of the these drugs make them a sec-
ond line of anti-epileptic treatment for these conditions, except for TN. Equivo-
cal or negative (active therapy not superior to placebo) results were reported 
with lamotrigine for spinal cord injury pain, HIV-related neuropathy and mixed 
neuropathies with topiramate for PDN as well as valproate for DPN and for spi-
nal cord injury pain [29].
Side effects of anticonvulsants
Carbamazepine (CBZ) entails frequent adverse events, which include se-
dation, dizziness, gait abnormalities. Liver enzymes, blood cells, platelets and 
sodium levels must be monitored for at least during 1 year, because of possible 
risk for hepatitis-anaplastic effects or hyponatremia. Induction of microsomal 
enzyme systems may influence the metabolism of several drugs. In contrast to 
CBZ, oxcarbazepine (OXC) does not entail enzymatic induction and there is li-
ttle risk for crossed cutaneous allergy. In the first months of treatment, sodium 
levels must be monitored because OXC, like CBZ induces hyponatraemia, parti-
cularly in the elderly (6% in a cohort of 54 patients). As regards other side-effects, 
although a better tolerance has been claimed with OXC compared with CBZ, this 
notion lacks consistent evidence from class I trials. In a recent trial in diabetic 
painful polyneuropathy, 27.5% of the OXC group discontinued treatment due to 
central or gastrointestinal side-effects versus 8% with the placebo. 
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The most common side-effects of gabapentin (GBP) and pregabalin include 
dizziness, somnolence, peripheral edema, and dry mouth, with a similar frequ-
ency for both drugs. Whilst GBP is widely accepted as highly tolerable even at 
high dosages (>2400 mg), the reports on pregabalin change remarkably with the 
daily dose: with 150 to 300 mg there is almost no difference with placebo, whilst 
the withdrawal rate reaches 20% with 600 mg. 
Lamotrigine is generally well tolerated. Side-effects include dizziness, na-
usea, headache and fatigue. However, it may induce potentially severe allergic 
skin reactions. Lamotrigine should not be used in combination with valproate. 
oPIoIds 
Eight RCTs tested the efficacy of oral opioids for PDN, PHN, phantom pain 
and neuropathic pain of diverse etiologies. Four drugs were tested: morphine, 
oxycodone, methadone and levorphanol. All trials reported that opioids were 
efficacious in reducing spontaneous neuropathic pain by demonstrating either 
superiority over placebo or a dose-dependent analgesic response. Six of the eight 
studies were recently pooled to a meta-analysis, which found a mean pain in-
tensity to be 14 points lower in opioid-treated patients than in those treated with 
placebo (95% C.I. -18 to -10; p<0.001) [16,17]. The overall NNT of opioids for neu-
ropathic pain is 2.5 (CI 2.0-3.2). Secondary outcome parameters such as physical 
and mental health, sleep and disability were measured in parts of these trials 
and yielded inconsistent results. Tramadol, which is not a typical opioid, yet has 
a weak affinity for opioid receptors, has been effective for DPN and PHN with 
NNT of 3.9 (CI 2.7-6.7) [5]. Common adverse events of opioids include nausea, 
constipation, dizziness and drowsiness, had seen an average of 8 different phy-
sicians prior to referral to the pain clinic [30,31].
Side effects
The most common side-effects of opioids are constipation, sedation, nausea, 
dizziness and vomiting. The risk of cognitive impairment has been reported to 
be negligible, although morphine may impair attention at very high dosages. 
Tramadol has been reported to induce dizziness, dry mouth, nausea, constipa-
tion and somnolence with significantly more dropouts compared with placebo. 
There is an increased risk of seizures in patients with a history of epilepsy or re-
ceiving drugs which may reduce the seizure threshold. Serotonergic syndrome 
(various combinations of myoclonus, rigidity, hyperreflexia, shivering, confu-
sion, agitation, restlessness, coma, autonomic instability, fever, nausea, diar-
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rhoea, flushing, and rarely, rhabdomyolysis and death) may occur if tramadol 
is used as an add-on treatment to other serotonergic medications (particularly 
selective serotonin reuptake inhibitors [SSRIs]). 
toPIcal agents 
Topical capsaicin cream has shown efficacy for DPN and PHN but its use is 
associated with burning, particularly during the first weeks of treatment. This 
can be problematic, especially for patients who experience allodynia in the first 
place. Application of topical lidocaine patches has been found effective for PHN 
in three short-term RCTs and can also be used in patients with other focal pe-
ripheral neuropathies [32,33].
drug combInatIons 
While combinations of drugs with different mechanisms of action are com-
monly used in clinical practice, only one trial tested the efficacy and safety of a 
combination of two drugs, and found that gabapentin plus morphine was more 
efficacious and safer than each drug alone [16]. This trial implies the possibility 
that polypharmcotherapy could enhance analgesia with fewer side effects.
non-InvasIve theraPIes
One of the simplest forms of non-invasive treatment for pain is transcuta-
neous electrical nerve stimulation (TENS). This has been used since the 1960s, 
following the development of the gate control theory of pain transmission by 
Melzack and Wall [8]. The technique is based on the interaction between small 
and large afferent fibers, which converge on the dorsal horn neurons before pro-
jecting to higher centers, and is a useful adjunctive treatment that is virtually 
free from adverse effects [34].
InvasIve theraPIes
The range of neurosurgical techniques used to treat neuropathic pain has 
increased over time, and includes nerve modulation (e.g., dorsal column stimu-
lation) as well as neural ablation [34]. Numerous ablative surgical techniques 
to destroy nerves have been described, including nerve avulsion or section, 
dorsal rhizotomy, spinal dorsal root entry zone lesions, spinothalamic tracto-
tomies, thalamotomies, cingulotomy, frontal lobotomy, and even destruction of 
the primary sensory cortex. However, these treatments are generally not recom-
101
Rad 504. Medical Sciences 33(2009):93-104.
V. Bašić Kes et al.: Neuropathic pain.
mended as they cause more damage to the nervous system, which can intensify 
the neuropathic pain. Furthermore, none of these surgical techniques has been 
found to be uniformly successful in treating patients with neuropathic pain. In-
deed, there are many examples in the literature of patients who have undergone 
surgical therapies to treat pain (e.g., due to nerve injury, trigeminal neuralgia, 
amputation, or post-herpetic neuralgia), only to find that surgery has exacer-
bated their original pain.
An invasive treatment regimen that is supported by some clinical evidence, 
and a fairly convincing rationale, is spinal cord dorsal column stimulation. As 
with TENS, this technique attempts to modulate rostral nociceptive transmis-
sion in the spinal cord by stimulation of the large diameter nerve fibers. Success 
depends on patient selection, and it is generally accepted that patients also suf-
fering some ischemic pain are particularly suited to this method of treatment 
[35]. The major advantage of this technique is that nerves are not deliberately 
damaged. Similarly, clinical evidence supports the use of microvascular de-
compression in providing relatively good long-term outcome for patients with 
trigeminal neuralgia [36]. Temporary nerve blocks achieved by injection of local 
anesthetic (e.g., lidocaine), are still sometimes used, though efficacy is controver-
sial and few placebo-controlled trials of this therapy have been performed [5].
The available data clearly indicate that approaches to the clinical manage-
ment of neuropathic pain vary according to whether the patient is being treated 
by a pain specialist or by a non-specialist. While non-specialists tend to treat 
individual symptoms, pain specialists are more likely to select a drug therapy 
that is targeted towards the mechanisms that are presumed to be causing pain 
in an individual patient or the anti-neuralgic mechanisms of various drugs [6]. 
The available data clearly indicate that patients treated in specialized pain clin-
ics are more likely to receive therapies with proven efficacy for the treatment of 
neuropathic pain than those treated in non-specialist clinics [37-40]
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Sažetak
Neuropatska bol
Neuropatska bol nastaje kao posljedica disfunkcije perifernog ili centralnog živčanog su-
stava. Najčešći uzroci neuropatske boli su diabetes melitus, reaktivacija herpes zoster infekcije, 
kompresija živaca ili radikulopatija, pretjerana konzumacija alkohola, kemoterapija ili zloupora-
ba lijekova te neuralgija trigeminusa. 
Specifični simptomi neuropatske boli su mehanička alodinija i hladna hiperalgezija.
U liječenju neuropatske boli koristi se nekoliko skupina lijekova. U prvu skupinu spadaju 
adjuvantni lijekovi, a to su antidepresivi i antiepileptici, opioidi i topički agensi. U praksi se naj-
češće koristi kombinacija dvije ili više vrsta lijekova.
Unatoč brojnim randomiziranim, placebo-kontroliranim studijama na području neuropatske 
boli, medikamentozno liječenje neuropatske boli još uvijek nije zadovoljavajuće, te se samo u 
50% pacijenata sa neuropatskom boli postiže zadovoljavajuća analgezija.
Ključne riječi: neuropatska bol; etiologija; liječnje.
